// App-Quantinova.ai

582 : Influence Of Active Cancer On The Efficacy and Safety Of Dabigatran Versus Warfarin For The Treatment Of Acute Venous Thromboembolism: A Pooled Analysis From RE-Cover and RE-Cover II

Researchers

Presenter

  • Sam Schulman

Principal Investigators

  • Henry Eriksson

  • Samuel Z Goldhaber

  • Ajay Kakkar

  • Clive Kearon

  • Sebastian M Schellong

  • Martin Feuring

  • Nuala Peter

  • Jeffrey Friedman

Medical Centers

  • Cardiovascular Division, Brigham and Womens Hospital, Harvard Medical School, Boston, MA

  • Department of Medicine, Sahlgrenska University Hospital-Ostra, Gothenburg, Sweden

  • Department of Medicine, McMaster University, Hamilton, ON, Canada

  • Medical Division , Municipal Hospital Friedrichstadt, Dresden, Germany

  • McMaster University, Hamilton, ON, Canada

  • Thrombosis Research Institute and University College London, London, United Kingdom

Locations

  • Canada

  • Germany

  • United Kingdom

  • United States

  • Sweden

Companies

  • Boehringer Ingelheim

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Cutaneous squamous cell carcinoma

  • Venous thrombosis

  • Arrhythmia

  • Solid malignancies

  • Stroke

Biomarkers

  • N/A

Drug/Treatment

  • Pradax

  • Hydroxyzine

  • Evithrom

  • Warfarin

Outcome

  • N/A

Study Design

  • randomized

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved